These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 18089850)

  • 1. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification.
    Gadner H; Grois N; Pötschger U; Minkov M; Aricò M; Braier J; Broadbent V; Donadieu J; Henter JI; McCarter R; Ladisch S;
    Blood; 2008 Mar; 111(5):2556-62. PubMed ID: 18089850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.
    Gadner H; Minkov M; Grois N; Pötschger U; Thiem E; Aricò M; Astigarraga I; Braier J; Donadieu J; Henter JI; Janka-Schaub G; McClain KL; Weitzman S; Windebank K; Ladisch S;
    Blood; 2013 Jun; 121(25):5006-14. PubMed ID: 23589673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.
    Minkov M
    Paediatr Drugs; 2011 Apr; 13(2):75-86. PubMed ID: 21351807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.
    Narula G; Pradhan ND; Arora B; Banavali SD
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
    Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
    Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study.
    Cui L; Wang CJ; Lian HY; Zhang L; Ma HH; Wang D; Chen FF; Zhang Q; Yang Y; Wei A; Huang XT; Zhu T; Wang TY; Li ZG; Zhang R
    Am J Hematol; 2023 Apr; 98(4):598-607. PubMed ID: 36594188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Egyptian experience in Langerhans cells histiocytosis: frequent multisystem affection and reactivation rates.
    Tantawy AAG; Ragab IA; Elsherif NHK; Makkeyah SM; AbdelRaheem HG; Elsantiel HIE
    Pediatr Hematol Oncol; 2020 Nov; 37(8):696-706. PubMed ID: 32706277
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment Outcome of Children With Multisystem Langerhans Cell Histiocytosis: The Experience of a Single Children's Hospital in Shanghai, China.
    Gao YJ; Su M; Tang JY; Pan C; Chen J
    J Pediatr Hematol Oncol; 2018 Jan; 40(1):e9-e12. PubMed ID: 29200145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
    Morimoto A; Shioda Y; Imamura T; Kudo K; Kawaguchi H; Sakashita K; Yasui M; Koga Y; Kobayashi R; Ishii E; Fujimoto J; Horibe K; Bessho F; Tsunematsu Y; Imashuku S
    Int J Hematol; 2016 Jul; 104(1):99-109. PubMed ID: 27040279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensification of treatment with vinca alkaloid does not improve outcomes in pediatric patients with Langerhans cell histiocytosis: results from the JPLSG LCH-12 study.
    Morimoto A; Shioda Y; Kudo K; Kanegane H; Imamura T; Koh K; Kosaka Y; Yuza Y; Nakazawa A; Saito AM; Watanabe T; Nakazawa Y
    Int J Hematol; 2023 Jul; 118(1):107-118. PubMed ID: 36871086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiating skin-limited and multisystem Langerhans cell histiocytosis.
    Simko SJ; Garmezy B; Abhyankar H; Lupo PJ; Chakraborty R; Lim KP; Shih A; Hicks MJ; Wright TS; Levy ML; McClain KL; Allen CE
    J Pediatr; 2014 Nov; 165(5):990-6. PubMed ID: 25441388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society.
    Weitzman S; Braier J; Donadieu J; Egeler RM; Grois N; Ladisch S; Pötschger U; Webb D; Whitlock J; Arceci RJ
    Pediatr Blood Cancer; 2009 Dec; 53(7):1271-6. PubMed ID: 19731321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis.
    Gadner H; Grois N; Arico M; Broadbent V; Ceci A; Jakobson A; Komp D; Michaelis J; Nicholson S; Pötschger U; Pritchard J; Ladisch S;
    J Pediatr; 2001 May; 138(5):728-34. PubMed ID: 11343051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood.
    Aricò M; Astigarraga I; Braier J; Donadieu J; Gadner H; Glogova E; Grois N; Henter JI; Janka G; McClain KL; Ladisch S; Pötschger U; Rosso D; Thiem E; Weitzman S; Windebank K; Minkov M;
    Br J Haematol; 2015 Apr; 169(2):241-8. PubMed ID: 25522229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study.
    Tazi A; Lorillon G; Haroche J; Neel A; Dominique S; Aouba A; Bouaziz JD; de Margerie-Melon C; Bugnet E; Cottin V; Comont T; Lavigne C; Kahn JE; Donadieu J; Chevret S
    Orphanet J Rare Dis; 2017 May; 12(1):95. PubMed ID: 28532436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Craniofacial involvement in Langerhans cell histiocytosis: A review of 44 cases at a single medical center.
    Lin TE; Chu YY; Chang TY; Liao HT
    J Plast Reconstr Aesthet Surg; 2023 Jul; 82():12-20. PubMed ID: 37148805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating cell-free BRAF
    Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
    Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group.
    Gadner H; Heitger A; Grois N; Gatterer-Menz I; Ladisch S
    Med Pediatr Oncol; 1994; 23(2):72-80. PubMed ID: 8202045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical manifestations of Langerhans cell histiocytosis with multisystem involvement in 53 children].
    Tang JJ; Xu XJ; Wang YC; Bai ST; Wang L; Ni XL; Liu YF
    Zhonghua Er Ke Za Zhi; 2021 Jan; 59(1):37-41. PubMed ID: 33397002
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical features and treatment outcomes of Langerhans cell histiocytosis: a nationwide survey from Korea histiocytosis working party.
    Kim BE; Koh KN; Suh JK; Im HJ; Song JS; Lee JW; Kang HJ; Park KD; Shin HY; Choi HS; Lee SH; Yoo KH; Sung KW; Koo HH; Jung HL; Chung NG; Cho B; Kim HK; Lyu CJ; Baek HJ; Kook H; Park JE; Park HJ; Park BK; Yoo ES; Ryu KH; Lee KS; Kim HS; Lee JM; Park ES; Yoon HS; Lee KC; Lee MJ; Lim YT; Kim HM; Park SK; Park JA; Kim SK; Park M; Lim YJ; Lee YH; Seo JJ;
    J Pediatr Hematol Oncol; 2014 Mar; 36(2):125-33. PubMed ID: 24276037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.